These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35672434)

  • 1. Long-term persistence of treatment after hip fracture in a fracture liaison service.
    Naranjo A; Molina A; Quevedo A; Rubiño FJ; Sánchez-Alonso F; Rodríguez-Lozano C; Ojeda S
    Sci Rep; 2022 Jun; 12(1):9373. PubMed ID: 35672434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fracture liaison service model: treatment persistence 5 years later.
    Naranjo A; Molina A; Quevedo A; Rubiño FJ; Sánchez-Alonso F; Rodríguez-Lozano C; Ojeda S
    Arch Osteoporos; 2021 Apr; 16(1):60. PubMed ID: 33813663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence with osteoporosis treatment in patients from the Lille University Hospital Fracture Liaison Service.
    Delbar A; Pflimlin A; Delabrière I; Ternynck C; Chantelot C; Puisieux F; Cortet B; Paccou J
    Bone; 2021 Mar; 144():115838. PubMed ID: 33385615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study.
    Senay A; Fernandes JC; Delisle J; Morin SN; Perreault S
    Arch Osteoporos; 2019 Aug; 14(1):87. PubMed ID: 31375983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
    Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
    JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
    Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
    Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore.
    Chau YT; Nashi N; Law LS; Goh RKH; Choo SX; Seetharaman SK
    Arch Osteoporos; 2020 Sep; 15(1):141. PubMed ID: 32918196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture.
    Naranjo A; Fernández-Conde S; Ojeda S; Torres-Hernández L; Hernández-Carballo C; Bernardos I; Rodríguez S; Laynez P
    Arch Osteoporos; 2017 Dec; 12(1):112. PubMed ID: 29230540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
    Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
    Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of eligibility for denosumab in patients presenting with osteoporotic fractures and renal impairment treated by orthogeriatric service at Middlemore Hospital.
    Kang MY; Besley J; Sun T; Paul S
    N Z Med J; 2020 May; 133(1515):16-24. PubMed ID: 32438373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
    Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
    JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture liaison services combined with online home nursing care in fragility hip fracture: a comparative effectiveness pilot study.
    Lai H; Fan J; Liu H; Wu X; Wang L; Gao L; Zhou L; Chen T; Zhang L; Chen J; Luo Z
    Arch Osteoporos; 2023 Feb; 18(1):33. PubMed ID: 36809579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refracture following fracture liaison service assessment illustrates the requirement for integrated falls and fracture services.
    Langridge CR; McQuillian C; Watson WS; Walker B; Mitchell L; Gallacher SJ
    Calcif Tissue Int; 2007 Aug; 81(2):85-91. PubMed ID: 17629737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of osteoporotic refractures in regional Australia.
    Davidson E; Seal A; Doyle Z; Fielding K; McGirr J
    Aust J Rural Health; 2017 Dec; 25(6):362-368. PubMed ID: 28618161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year outcomes of a fracture liaison service model at a university-based tertiary care hospital in Thailand.
    Chotiyarnwong P; Kitcharanant N; Vanitcharoenkul E; Anusitviwat C; Jarusriwanna A; Suthutvoravut W; Boonnasa W; Unnanuntana A
    Arch Osteoporos; 2023 Jan; 18(1):26. PubMed ID: 36692851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.